Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Heparinised saline is a standard, extemporaneously prepared clinical formulation consisting of the anticoagulant heparin dissolved in normal saline (0.9% sodium chloride). It is widely used in clinical settings as a catheter lock or flush solution to maintain the patency of intravenous and arterial catheters by preventing blood clot formation. Additionally, heparinised saline has been evaluated as an intraperitoneal hydroflotation and irrigation fluid following laparoscopic adhesiolysis to reduce the recurrence of peritoneal adhesions and alleviate chronic pelvic pain. Its active ingredient, heparin, acts by binding to and activating antithrombin III, which subsequently inactivates thrombin and factor Xa, thereby inhibiting the coagulation cascade and promoting fibrinolysis. Despite its widespread use for catheter maintenance, evidence for its efficacy in reducing peritoneal adhesions after pelvic surgery remains unestablished.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on heparinised saline.